Effects of intranasal insulin on cognition and mobility studied in older adults – Consumer Health News
THURSDAY, May 5, 2022 (HealthDay News) — For older adults with type 2 diabetes (T2D), intranasal insulin (INI) may have positive effects on cognition and gait, according to a study published online on April 28 in Journal of Neurology.
Vera Novak, Ph.D., MD, of Harvard Medical School in Boston, and colleagues conducted a phase 2, randomized, double-blind trial consisting of 24 weeks of treatment with INI or placebo once daily and 24 weeks follow-up. A total of 223 elderly adults with (DM) and without T2D (controls) were included (51 DM-INI, 55 DM-placebo, 58 controls-INI and 59 controls-placebo); 174 completed treatment and 156 completed follow-up. Primary outcomes included cognition, normal walking speed (NW), and dual task walking speed (DTW).
The researchers found that compared to DM-placebo, DM-INI had faster NW processing, but not DTW. Compared to control-placebo, control-INI had better executive functioning during treatment and post-treatment and better verbal memory after treatment. Faster walking and better executive function and verbal memory were observed for INI (combined DM-INI and control-INI groups). No association was observed between INI and serious adverse events, hypoglycaemic episodes or weight gain.
“Overall, the INI effect demonstrated improvements in walking speed, executive function, and verbal memory,” the authors write. “These findings are clinically relevant and warrant further investigation in a larger clinical trial.”
Several authors disclosed financial ties to medical device and pharmaceutical companies, including Novo Nordisk, which manufactures INI and partially funded the study.